LexAurum Advisors LLC Has $129,000 Stock Position in Precigen, Inc. (NASDAQ:PGEN)

LexAurum Advisors LLC lessened its position in shares of Precigen, Inc. (NASDAQ:PGEN) by 8.8% in the first quarter, according to its most recent filing with the SEC. The firm owned 89,166 shares of the biotechnology company’s stock after selling 8,600 shares during the quarter. LexAurum Advisors LLC’s holdings in Precigen were worth $129,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Fisher Asset Management LLC bought a new position in Precigen during the fourth quarter worth $29,000. Opaleye Management Inc. lifted its stake in shares of Precigen by 9.0% in the 4th quarter. Opaleye Management Inc. now owns 1,012,500 shares of the biotechnology company’s stock valued at $1,357,000 after purchasing an additional 84,000 shares during the period. Patient Capital Management LLC boosted its position in shares of Precigen by 16.2% during the 4th quarter. Patient Capital Management LLC now owns 15,983,700 shares of the biotechnology company’s stock valued at $21,418,000 after purchasing an additional 2,230,524 shares in the last quarter. Panagora Asset Management Inc. acquired a new stake in Precigen during the fourth quarter worth approximately $407,000. Finally, Emfo LLC increased its holdings in Precigen by 22.2% in the fourth quarter. Emfo LLC now owns 519,475 shares of the biotechnology company’s stock worth $696,000 after purchasing an additional 94,475 shares in the last quarter. Institutional investors own 33.51% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. StockNews.com raised shares of Precigen to a “sell” rating in a research report on Tuesday, May 21st. JMP Securities reiterated a “market outperform” rating and set a $14.00 price objective on shares of Precigen in a report on Tuesday, June 4th. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Precigen in a research note on Monday, June 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Precigen in a research report on Wednesday, May 15th. Finally, Stifel Nicolaus increased their price target on Precigen from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, June 3rd. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Precigen currently has a consensus rating of “Hold” and an average target price of $10.00.

Precigen Trading Up 0.7 %

Shares of NASDAQ PGEN opened at $1.54 on Friday. The company has a 50-day moving average price of $1.45 and a 200-day moving average price of $1.41. Precigen, Inc. has a 1 year low of $0.84 and a 1 year high of $1.88.

Precigen (NASDAQ:PGEN) last released its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The company had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.54 million. Precigen had a negative net margin of 1,781.72% and a negative return on equity of 65.36%. During the same quarter last year, the firm posted ($0.10) EPS. On average, research analysts anticipate that Precigen, Inc. will post -0.36 EPS for the current fiscal year.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.